IN2014DN06117A - - Google Patents

Info

Publication number
IN2014DN06117A
IN2014DN06117A IN6117DEN2014A IN2014DN06117A IN 2014DN06117 A IN2014DN06117 A IN 2014DN06117A IN 6117DEN2014 A IN6117DEN2014 A IN 6117DEN2014A IN 2014DN06117 A IN2014DN06117 A IN 2014DN06117A
Authority
IN
India
Prior art keywords
buprenorphine
methods
delivery device
environment
buffered
Prior art date
Application number
Other languages
English (en)
Inventor
Andrew Finn
Niraj Vasisht
Original Assignee
Biodelivery Sciences Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodelivery Sciences Int Inc filed Critical Biodelivery Sciences Int Inc
Publication of IN2014DN06117A publication Critical patent/IN2014DN06117A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN6117DEN2014 2011-12-21 2012-12-21 IN2014DN06117A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578755P 2011-12-21 2011-12-21
PCT/US2012/071330 WO2013096811A2 (en) 2011-12-21 2012-12-21 Transmucosal drug delivery devices for use in chronic pain relief

Publications (1)

Publication Number Publication Date
IN2014DN06117A true IN2014DN06117A (es) 2015-08-14

Family

ID=48669710

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6117DEN2014 IN2014DN06117A (es) 2011-12-21 2012-12-21

Country Status (16)

Country Link
EP (1) EP2793870A4 (es)
JP (1) JP6255349B2 (es)
KR (4) KR20210003313A (es)
CN (2) CN104125828A (es)
AU (4) AU2012358308A1 (es)
BR (1) BR112014015329A2 (es)
CA (1) CA2859859A1 (es)
EA (2) EA201992762A1 (es)
HK (1) HK1203365A1 (es)
IL (2) IL233075A0 (es)
IN (1) IN2014DN06117A (es)
MX (2) MX362217B (es)
SG (3) SG10202012743WA (es)
UA (1) UA118540C2 (es)
WO (1) WO2013096811A2 (es)
ZA (1) ZA201804381B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
OA12215A (en) 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
CA2445346C (en) 2001-04-27 2010-04-06 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US9522188B2 (en) 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
CA2649107A1 (en) 2006-04-12 2007-10-25 Spinal Motion, Inc. Posterior spinal device and method
MX2009000745A (es) * 2006-07-21 2009-04-16 Biodelivery Sciences Int Inc Dispositivos de suministro transmucosa con admision mejorada.
EP1897543A1 (en) * 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
GB0620661D0 (en) * 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CN102056578A (zh) * 2008-06-23 2011-05-11 生物递送科学国际公司 多向粘膜给药装置及使用方法
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Also Published As

Publication number Publication date
ZA201804381B (en) 2022-12-21
AU2017258916B2 (en) 2019-01-17
EA201992762A1 (ru) 2020-07-31
KR20140106720A (ko) 2014-09-03
WO2013096811A3 (en) 2014-07-24
MX2021012154A (es) 2021-11-03
BR112014015329A8 (pt) 2017-06-13
MX2014007350A (es) 2014-09-15
EP2793870A2 (en) 2014-10-29
JP2015500886A (ja) 2015-01-08
CN110123792A (zh) 2019-08-16
SG10202012743WA (en) 2021-01-28
KR20220047889A (ko) 2022-04-19
KR20210003313A (ko) 2021-01-11
BR112014015329A2 (pt) 2017-06-13
EA201491046A1 (ru) 2014-11-28
IL233075A0 (en) 2014-07-31
HK1203365A1 (en) 2015-10-30
SG11201403075XA (en) 2014-07-30
AU2017258916A1 (en) 2017-11-30
UA118540C2 (uk) 2019-02-11
SG10201710667YA (en) 2018-02-27
AU2012358308A1 (en) 2014-07-24
AU2019202602A1 (en) 2019-05-02
EP2793870A4 (en) 2016-02-17
KR102026321B1 (ko) 2019-09-27
CA2859859A1 (en) 2013-06-27
WO2013096811A2 (en) 2013-06-27
IL285091A (en) 2021-08-31
KR20190110628A (ko) 2019-09-30
EA034529B1 (ru) 2020-02-18
JP6255349B2 (ja) 2017-12-27
AU2021202042A1 (en) 2021-04-29
CN104125828A (zh) 2014-10-29
MX362217B (es) 2019-01-09

Similar Documents

Publication Publication Date Title
MX2009000745A (es) Dispositivos de suministro transmucosa con admision mejorada.
TN2015000027A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA200801575A1 (ru) Трансдермальная доставка мептазинола
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
WO2010042471A3 (en) Medical devices for delivery of therapeutic agents to body lumens
WO2015066647A3 (en) Ionic liquids for transdermal drug delivery
MX342001B (es) Tratamiento de artritis por lupus usando laquinimod.
MX352959B (es) Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
WO2014153385A3 (en) Methods of treating metabolic disorders
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2013083826A3 (en) Glp-1 agonists
IN2014DN06117A (es)
UA106131C2 (uk) Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
UA115250C2 (uk) Фармацевтичні комбінації
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
NZ724912A (en) Transmucosal drug delivery devices for use in chronic pain relief
MX357376B (es) Composicion farmaceutica para uso en inflamacion y dolor.
MX2010004457A (es) Idarubicina para el tratamiento de linfoma en un perro.
UA33217U (ru) Способ лечения больных хроническими дерматозами
UA96455C2 (ru) Средства для трансмукозальной доставки лекарства, которые обеспечивают их усиленное усвоение